Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP

Royce & Associates LP lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,021,105 shares of the biopharmaceutical company's stock after selling 140,917 shares during the period. Royce & Associates LP owned approximately 1.70% of Catalyst Pharmaceuticals worth $40,180,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $50,000. CWM LLC raised its holdings in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Catalyst Pharmaceuticals during the second quarter valued at $70,000. Finally, SG Americas Securities LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter valued at $173,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

CPRX stock traded down $1.09 during mid-day trading on Friday, reaching $20.60. The company had a trading volume of 1,708,449 shares, compared to its average volume of 1,196,733. The firm has a fifty day simple moving average of $20.97 and a 200 day simple moving average of $18.28. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 3.51 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.00 and a fifty-two week high of $24.27.

Insiders Place Their Bets

In related news, insider Steve Miller sold 150,000 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares of the company's stock, valued at $13,738,773.40. This trade represents a 18.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David S. Tierney sold 15,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. The trade was a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CPRX shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Monday. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. Finally, Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $30.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.